SG11202003949TA - Method for inactivating zika virus and for determining the completeness of inactivation - Google Patents

Method for inactivating zika virus and for determining the completeness of inactivation

Info

Publication number
SG11202003949TA
SG11202003949TA SG11202003949TA SG11202003949TA SG11202003949TA SG 11202003949T A SG11202003949T A SG 11202003949TA SG 11202003949T A SG11202003949T A SG 11202003949TA SG 11202003949T A SG11202003949T A SG 11202003949TA SG 11202003949T A SG11202003949T A SG 11202003949TA
Authority
SG
Singapore
Prior art keywords
completeness
inactivation
determining
zika virus
inactivating
Prior art date
Application number
SG11202003949TA
Other languages
English (en)
Inventor
Jill A Livengood
Holli Giebler
Hansi Dean
Tatsuki Satou
Raman Rao
Jackie Marks
Mark Lyons
Asae Shintani
Jamie Gifford
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of SG11202003949TA publication Critical patent/SG11202003949TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SG11202003949TA 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation SG11202003949TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581500P 2017-11-03 2017-11-03
US201762592995P 2017-11-30 2017-11-30
PCT/US2018/059227 WO2019090233A2 (fr) 2017-11-03 2018-11-05 Procédé pour inactiver le virus zika et pour déterminer la complétude de l'inactivation

Publications (1)

Publication Number Publication Date
SG11202003949TA true SG11202003949TA (en) 2020-05-28

Family

ID=64427224

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11202003949TA SG11202003949TA (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation
SG11202003796XA SG11202003796XA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003800YA SG11202003800YA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG11202003796XA SG11202003796XA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003800YA SG11202003800YA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Country Status (12)

Country Link
US (5) US11478541B2 (fr)
EP (3) EP3703739A2 (fr)
JP (4) JP2021502350A (fr)
KR (3) KR20200085302A (fr)
CN (3) CN111526885A (fr)
AU (6) AU2018359558C1 (fr)
BR (3) BR112020008652A2 (fr)
CA (3) CA3081586A1 (fr)
MX (3) MX2020004543A (fr)
MY (2) MY194449A (fr)
SG (3) SG11202003949TA (fr)
WO (3) WO2019090228A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090228A2 (fr) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Vaccins et compositions immunogènes anti-zika, et leurs procédés d'utilisation
CN111601885A (zh) 2017-11-30 2020-08-28 武田疫苗股份有限公司 用于将寨卡病毒灭活的方法和相关方法
EP3965811A1 (fr) * 2019-05-08 2022-03-16 Takeda Vaccines, Inc. Compositions de virus inactivé et formulations de vaccin à base de zika
US20230324404A1 (en) 2020-05-20 2023-10-12 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
US20240133887A1 (en) 2020-10-08 2024-04-25 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
CN112980805B (zh) * 2021-02-25 2022-11-08 中国科学院广州生物医药与健康研究院 一种重组寨卡病毒减毒株及其制备方法和应用
CN112941201B (zh) * 2021-03-01 2022-03-08 武汉珈创生物技术股份有限公司 一种用于多细胞种属鉴别和交叉污染检测的混合引物及其使用方法
WO2023154043A1 (fr) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Vaccins contre le zika et compositions immunogènes, et procédés d'utilisation associés
KR102619184B1 (ko) * 2022-12-27 2023-12-29 주식회사 그린백스 에피갈로카테킨-3-갈레이트에 의해 불활화된 지카바이러스를 유효성분으로 포함하는 백신 조성물

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1331443C (fr) 1987-05-29 1994-08-16 Charlotte A. Kensil Adjuvant a saponine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CN1087176C (zh) 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
ES2267100T5 (es) 1994-07-15 2011-04-08 The University Of Iowa Research Foundation Oligonucleótidos inmunomoduladores.
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
WO1997048440A1 (fr) 1996-06-18 1997-12-24 Alza Corporation Dispositif d'amelioration d'apport ou d'echantillonnage d'agents transdermiques
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ES2195190T3 (es) 1996-12-20 2003-12-01 Alza Corp Dispositivo y metodo para mejorar el flujo de agente transdermico.
AT405939B (de) 1997-02-24 1999-12-27 Immuno Ag Verfahren zur inaktivierung von lipidumhüllten viren
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
ES2382946T3 (es) 1997-08-28 2012-06-14 Cj Cheiljedang Corporation Virus de la encefalitis Japonesa atenuado
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
EP1021548A1 (fr) 1997-10-07 2000-07-26 University Of Maryland Biotechnology Institute Procede d'introduction et d'expression d'arn dans des cellules animales
WO1999027961A1 (fr) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Administration transdermique de compositions particulaires de vaccins
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
ES2257068T3 (es) 1998-08-10 2006-07-16 Antigenics Inc. Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas.
US6703233B1 (en) 1998-12-02 2004-03-09 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (fr) 1999-11-26 2001-05-30 Introgene B.V. Production de vaccins de lignées de cellules mammifère immortalisées
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
US7056700B2 (en) 2000-11-22 2006-06-06 University Of Maryland Use of ClyA hemolysin for excretion of proteins
GB0326439D0 (en) 2003-11-13 2003-12-17 Imp College Innovations Ltd Methods
US20080193478A1 (en) 2004-08-27 2008-08-14 Rajesh Jain Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus
ES2386272T3 (es) 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales
EP1724338A1 (fr) 2005-05-19 2006-11-22 Crucell Holland B.V. Méthode de production d'un vaccin de virus de West Nile inactivé complet
EP2073839B1 (fr) 2006-09-01 2016-10-19 Bharat Biotech International Limited Vaccin contre l'infection par le virus chikungunya
BRPI1012635A2 (pt) 2009-03-27 2016-06-21 Academia Sinica "métodos e composições para imunização contra o vírus"
US20100310656A1 (en) 2009-04-27 2010-12-09 Immunitor USA, Inc. Immunotherapy and prevention of autoimmune hepatitis
EA201391515A1 (ru) 2011-05-26 2014-05-30 Глаксосмитклайн Байлоджикалс С.А. Инактивированная вакцина вируса денге
AU2012269907B2 (en) 2011-06-17 2017-05-18 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
SI3106176T1 (en) 2011-12-06 2018-04-30 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
EP2823312B1 (fr) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro essai d'activite des vaccins a base de proteines méningococciques
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
AU2014338520B2 (en) 2013-09-14 2019-12-05 Bharat Biotech International Limited A viral vaccine and methods of manufacture thereof
SG11201702116VA (en) 2014-09-17 2017-04-27 Univ Iowa Res Found Viral rna segments as immunomodulatory agents and vaccine components
CU24510B1 (es) 2014-10-07 2021-05-12 Serum Institute Of India Pvt Ltd Método para la composición de una vacuna contra la poliomielitis, con poliovirus inactivados y adsorción en coadyuvantes
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
WO2016145149A1 (fr) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Vaccin inactivé, purifié et combiné pour les flavivirus
US20180185467A1 (en) 2015-06-22 2018-07-05 President And Fellows Of Harvard College Compositions and methods for modulating viral infection
WO2017009873A1 (fr) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Compositions de vaccin
ES2937963T3 (es) 2015-07-21 2023-04-03 Modernatx Inc Vacunas de enfermedad infecciosa
WO2017056094A1 (fr) 2015-09-30 2017-04-06 Ramot At Tel-Aviv University Ltd. Virus atténués ayant muté au niveau de sites à structure d'arn conservée au cours de l'évolution
EP3364950A4 (fr) 2015-10-22 2019-10-23 ModernaTX, Inc. Vaccins contre des maladies tropicales
EP3184119A1 (fr) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatographie basée sur des stratégies de purification pour les virus de la rougeole basés sur un échafaudage
FI3393510T3 (fi) 2015-12-23 2023-03-22 Valneva Austria Gmbh Zika-virusrokote
US11434259B2 (en) 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
CN109152826B (zh) 2016-02-25 2022-11-04 宾夕法尼亚大学理事会 新抗寨卡病毒疫苗
US20170354729A1 (en) 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
WO2017181098A2 (fr) 2016-04-15 2017-10-19 Visterra, Inc. Molécules d'anticorps se liant au virus zika et leurs utilisations
WO2017192856A1 (fr) 2016-05-04 2017-11-09 University Of Miami Vecteur du virus zika pour le traitement de l'infection par le virus zika
AU2017261705B2 (en) 2016-05-10 2024-04-18 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
US10967057B2 (en) 2016-06-02 2021-04-06 Glaxosmithkline Biologicals S.A. Zika viral antigen constructs
BR112018075440A2 (pt) 2016-06-09 2019-04-02 Beth Israel Deaconess Medical Center composições e métodos para prevenir e tratar a infecção por zika vírus
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
BR112018075513A2 (pt) 2016-06-13 2019-10-01 Us Health ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika
US10632185B2 (en) 2016-07-08 2020-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/zika viruses and methods of use
BR112018077041A2 (pt) 2016-07-08 2019-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale sequências genômicas que codificam para um vírus da zika mutante atuado
US11834494B2 (en) 2016-07-26 2023-12-05 Washington University Antibodies to zika virus and methods of use thereof
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
US11780885B2 (en) 2016-11-17 2023-10-10 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
US20190358313A1 (en) 2016-12-23 2019-11-28 Expres2Ion Biotechnologies Aps New flavivirus vaccine
CN108503697B (zh) 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 一种果蝇细胞表达的寨卡病毒亚单位疫苗
CN108503696B (zh) 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 一种酵母细胞表达的寨卡病毒亚单位疫苗
EP4205760A1 (fr) 2017-03-08 2023-07-05 University of Georgia Research Foundation, Inc. Procédés et compositions liés à une production virale accrue
WO2018187799A1 (fr) 2017-04-07 2018-10-11 The Rockefeller University Compositions et méthodes se rapportant à des anticorps neutralisants humains dirigés contre le virus zika et le virus de la dengue 1
WO2018237039A1 (fr) 2017-06-20 2018-12-27 Texas Tech University System Vaccin à base de pseudo-particules virales (vlp) zika et dosage de microneutralisation
EP3417943B1 (fr) 2017-06-21 2020-02-12 Eppendorf AG Rotor de centrifugeuse doté de joint d'étanchéité
CN107188935B (zh) * 2017-07-20 2018-10-02 北京健乃喜生物技术有限公司 一种寨卡病毒ns1抗原突变体及其应用
WO2019042555A1 (fr) 2017-08-31 2019-03-07 Humabs Biomed Sa Anticorps multispécifiques se liant spécifiquement aux épitopes du virus zika et leurs utilisations
CN107537029B (zh) 2017-09-14 2021-03-19 北京科兴生物制品有限公司 一种寨卡病毒与黄热病毒联合灭活疫苗
GB201716254D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
WO2019090228A2 (fr) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Vaccins et compositions immunogènes anti-zika, et leurs procédés d'utilisation
BR102017024030A2 (pt) 2017-11-08 2019-06-04 Universidade Federal De São João Del Rei Proteína recombinante imunogênica com antígenos de zika virus para vacina e seus usos
WO2019104157A1 (fr) 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Anticorps humains hautement spécifiques neutralisant le virus zika
CN111601885A (zh) 2017-11-30 2020-08-28 武田疫苗股份有限公司 用于将寨卡病毒灭活的方法和相关方法
CN108187036A (zh) 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 一种寨卡病毒与乙脑病毒联合灭活疫苗
CN108210921A (zh) 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 一种寨卡病毒疫苗及其制备方法
BR112019020526A2 (pt) 2018-02-22 2020-09-15 Nano4 Global, Lda método para detectar flaviviridae
RU2020132280A (ru) 2018-03-08 2022-04-11 Кодадженикс Инк. Аттенуированные флавивирусы
WO2019186199A1 (fr) 2018-03-29 2019-10-03 Emergex Vaccines Holding Limited Compositions vaccinales
KR102075581B1 (ko) 2018-04-27 2020-02-10 가톨릭대학교 산학협력단 바이러스성 발현 조절 서열이 삽입된 핵산 분자를 포함하는 면역보강제 및 이를 포함하는 약학 조성물
WO2020017765A1 (fr) 2018-07-18 2020-01-23 (주)진매트릭스 Variant du virus zika et composition de vaccin à base de zika le comprenant
WO2020051766A1 (fr) 2018-09-11 2020-03-19 上海市公共卫生临床中心 Immunogène pour vaccin à large spectre contre la grippe, et application de celui-ci
US20210308250A1 (en) 2018-10-26 2021-10-07 New York Blood Center, Inc. Zika virus immunogenic compositions
JP7463366B2 (ja) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
EP3965811A1 (fr) 2019-05-08 2022-03-16 Takeda Vaccines, Inc. Compositions de virus inactivé et formulations de vaccin à base de zika
WO2021262659A1 (fr) 2020-06-22 2021-12-30 University Of Connecticut Peptides signal de flavivirus, constructions de vaccins et méthodes associées

Also Published As

Publication number Publication date
AU2022201109B9 (en) 2022-05-12
US11648304B2 (en) 2023-05-16
BR112020008665A2 (pt) 2020-11-10
US20210177958A1 (en) 2021-06-17
SG11202003800YA (en) 2020-05-28
MX2020004367A (es) 2020-10-19
AU2018359556B2 (en) 2021-12-02
AU2022209239A1 (en) 2022-08-18
EP3703740A2 (fr) 2020-09-09
KR20200117981A (ko) 2020-10-14
AU2022201109A1 (en) 2022-03-10
CN111526885A (zh) 2020-08-11
WO2019090228A2 (fr) 2019-05-09
WO2019090233A2 (fr) 2019-05-09
JP2023175761A (ja) 2023-12-12
US11478541B2 (en) 2022-10-25
MX2020004543A (es) 2020-09-18
JP2021502075A (ja) 2021-01-28
WO2019090238A1 (fr) 2019-05-09
SG11202003796XA (en) 2020-05-28
MY193736A (en) 2022-10-27
AU2018359558A1 (en) 2020-05-28
US11730802B2 (en) 2023-08-22
AU2022209239B2 (en) 2023-10-05
AU2022201109B2 (en) 2022-04-28
US20210177959A1 (en) 2021-06-17
MX2020004542A (es) 2020-09-18
AU2018359660A1 (en) 2020-05-28
US20230145065A1 (en) 2023-05-11
MY194449A (en) 2022-11-30
AU2018359556A1 (en) 2020-05-28
KR20200085302A (ko) 2020-07-14
AU2022203422B2 (en) 2023-10-05
AU2018359558C1 (en) 2022-09-22
JP7443232B2 (ja) 2024-03-05
CN111615397A (zh) 2020-09-01
CN111511395A (zh) 2020-08-07
CA3081581A1 (fr) 2019-05-09
AU2018359660B2 (en) 2022-02-24
US20200360505A1 (en) 2020-11-19
EP3703741A1 (fr) 2020-09-09
KR20200083571A (ko) 2020-07-08
JP2021502350A (ja) 2021-01-28
WO2019090228A3 (fr) 2019-06-20
JP7295124B2 (ja) 2023-06-20
US20230414743A1 (en) 2023-12-28
BR112020008652A2 (pt) 2020-11-10
EP3703739A2 (fr) 2020-09-09
AU2022203422A1 (en) 2022-06-09
CA3081586A1 (fr) 2019-05-09
AU2018359558B2 (en) 2021-12-02
BR112020008693A2 (pt) 2020-10-13
US11964008B2 (en) 2024-04-23
CA3081578A1 (fr) 2019-05-09
JP2021505648A (ja) 2021-02-18
WO2019090233A3 (fr) 2019-06-13

Similar Documents

Publication Publication Date Title
SG11202003949TA (en) Method for inactivating zika virus and for determining the completeness of inactivation
HK1249058A1 (zh) 用於增强靶向蛋白質降解的化合物和方法
IL258533B (en) Acoustic orthopedic monitoring system and methods
SG11201606819QA (en) Compositions for the inactivation of virus replication and methods of making and using the same
IL247358B (en) Apparatus and method for disabling continuous virus activity
SG11202003975WA (en) Method for inactivating zika virus and related methods
HK1231402A1 (zh) 治療 型肝炎和 型肝炎病毒感染的方法
EP3206608A4 (fr) Systèmes et procédés de fixation d'os intermédullaire
HK1253377A1 (zh) 可編程的溶瘤病毒疫苗系統及其應用
SG10201908584SA (en) Fixed Dose Combinations And Formulations Comprising ETC1002 And One Or More Statins And Methods Of Treating Or Reducing The Risk Of Cardiovascular Disease
IL249400A0 (en) Orthopedic splints and methods for their production
EP3630175A4 (fr) Méthodes et dispositifs pour le traitement d'allergies alimentaires
IL270989A (en) Oncolytic virus and method
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
ZA201801164B (en) Method and device for disinfecting inner surfaces of freezers and the like
HK1253557A1 (zh) 純化和/或病毒滅活的方法
EP3731879A4 (fr) Système et procédés de stérilisation par plasma et de séchage
IL272779A (en) Methods to prevent viral infection
ZA202001060B (en) Nodes and methods for handling paging
HUE064361T2 (hu) Növények kezelésére szolgáló termékek és azokhoz kapcsolódó eljárások
IL274161A (en) Systems and methods for the treatment of hyper-IGM syndrome
PL3284351T3 (pl) Sposób pasteryzacji i/lub sterylizacji materiałów cząstkowych
EP3569687A4 (fr) Trousse d'inactivation de virus et dispositif d'inactivation de virus
ZA201705499B (en) Method for cooking and sterilization
GB201813832D0 (en) Centrifugal fan and method for cleaning thereof